Clinical Trial Update: Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer [Phase 1]

View source ↗

Summary

The Phase 1 trial evaluating irinotecan hydrochloride with FOLFIRI and cetuximab for first-line treatment of RAS wild-type colorectal cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• IRINOTECAN HYDROCHLORIDE (irinotecan hydrochloride)

Snippet

Sponsor: University of Chicago | Conditions: Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer | Phase 1 | Status: WITHDRAWN